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Introduction
Varicella is an infectious disease caused by a virus 
(VZV), identified almost a century ago, belonging to 
herpesvirus family [1].
The disease mostly affects younger age classes. Al-
though considered a mild disease, in some cases, espe-
cially in immunocompromised subjects, varicella can be 
severe, even fatal. The clinical course of the disease is 
longer in adults and more severe than in childhood [2].
VZV infection in susceptible pregnant woman, although 
rare, can cause severe forms both in the mother and in 
the newborn. A disabling congenital or neonatal vari-
cella syndrome can affect the offspring born to a woman 
who contracts VZV during pregnancy [3].
During primary infection, VZV has the ability to become 
latent in the sensory-nerve ganglia and to cause, many 
years later, the reactivated form, herpes zoster [4].
The epidemiological relevance of varicella and the 
availability of a live, attenuated, safe and effective 
vaccine [5, 6], have prompted an ample international 
debate on the opportunity of extensive infant varicella 
vaccination.
Recently, a new high-potency, live, attenuated varicella 
zoster vaccine has demonstrated able to reduce morbid-
ity and complications associated to zoster [7].
General microbiological and epidemio-
logical features
Varicella-Zoster virus (VZV) is an alphaherpesvirus, 
with a DNA genome, characterized by a lipoproteic en-
velope and a icosaedric capsid. The virus can spread by 
release of enveloped virions in the extra-cellular space or 
by cell to cell spread. The first case is typical of vescicu-
lar skin lesions and represents the lytic infection, while 
the latter is sustained by non-enveloped virions and is 
thought to be important during natural infection, contrib-
uting to the dissemination of viruses to the skin [8].
During primary infection, mainly during the exanthe-
matic phase, VZV has the ability to become latent in 
the sensory-nerve ganglia. The latent phase is character-
ized by the expression of only a small subset of viral 
proteins; when lytic infection develops, herpes zoster 
occurs [8, 9].
Varicella is an airborne disease; the virus spreads from 
person to person via Flugge droplets or via direct con-
tact with skin lesions of patients affected by varicella or 
zoster [10].
Man is the only reservoir of infection and varicella has a 
typical endemic-epidemic course. The disease mostly af-
fects childhood. The period of incubation ranges between 
14 and 16 days; this period could be longer (28 days) in 
subjects treated with specific immunoglobulins. The first 
period of infection involves various mucosal sites (na-
sopharynx, conjunctivae); subsequently the virus spreads 
to regional lymph nodes and after two viraemic phases 
causes the typical maculopapular-vesicular rash, char-
acterized by several crops of vesicles containing large 
amounts of enveloped virus. In immunocompromised 
patients viral replication persists longer and the clinical 
feature of infection can be more severe and complicated 
with pneumonia, encephalitis, cerebellitis, etc. [11]. 
Patients with varicella and zoster are both infectious. 
Contagiousness begins 1-2 days before the onset of rash 
and lasts until the last crop of vesicles has crusted.
From the clinical point of view, varicella is considered a 
benign disease. However, complications, such as cutane-
ous bacterial superinfections, upper and lower respiratory 
tract infections, conjunctivitis, corneal infections and SNC 
involvement, are possibile also in pediatric age [12-14]. 
The clinical course of infection acquired in adults is pro-
longed and more severe than in childhood [2]. The rela-
tion between frequency and severity of complications and 
older age of acquisition of infection is confirmed by the 
increased rate of hospitalization registered in adults [9]. 
The augmented rate of complicated forms of infections 
in adults is probably related to a lower cell-mediated im-
mune response than in children.
In pregnancy VZV infection, even if rare, can have a 
severe impact both on mother and offspring [3]:
– severe VZV in the mother, particularly if infection 
has been acquired in the third trimester of preg-
nancy;
– disseminated VZV in newborn, when the mother de-
velops the disease from 5 days before to 2 days after 
delivery;
– congenital syndrome, when the mother has acquired 
infection between the 8th and 20th week of preg-
nancy.
As mentioned before, reactivation of latent virus, years 
after primary infection, causes the clinical picture called 
zoster or shingles. Reactivation is directly related to a 
reduction of specific T-lymphocytes. During lifetime 
the risk of an episode of zoster is estimated equal to 10-
30% and incidence increases sharply in older ages [15, 
16]: 50% of people older than 85 yrs have at least one 
episode of zoster.
Clinically, zoster is characterized by a dermatomal 
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painful vesicular rash lasting, in the immunocompetent 
patient, 2-3 weeks. In a certain percentage of patients 
pain persists for several weeks or for months or years 
after disappearance of the rash. This chronic pain, called 
post-herpetic neuralgia (PHN), represents an important 
cause of stress and disability and significantly contrib-
utes to worsening the patients’ quality of life [17].
Decay of the cell-mediated immune response and in-
creasing age represent important risk factors for zoster; 
intrauterine exposure and VZV acquisition before 18 
months of age are also related to an increased risk of 
zoster. No clear relation has turned out for other risk 
factors such as gender, stagionality, race, psychological 
stress, exposure to immunotoxic chemical substances, 
mechanical traumas and genetic susceptibility [18].
All updated studies confirm the impact of zoster on 
population in terms of morbidity, rate and lenght of 
hospitalization, worsening of the clinical conditions of 
patients affected by other pathologies. All these param-
eters increase significantly in older subjects [19].
Immunological aspects
VZV natural infection induces a long lasting immune 
response against clinical disease; during primary infec-
tion the immune system is activated and produces first 
IgM and subsequently IgG. These latter seem to persist 
lifelong, eventhough some studies hypotize that the per-
sistence of immunity depends on both exogenous and 
endogenous boosters. However, naturally acquired im-
munity following VZV infection does not prevent virus 
latentization nor subsequent reactivation in zoster.
During natural infection there is an activation of 
both humoral and cellular branch of the immune 
system [10, 20, 21].
The absence of anti-VZV antibodies does not neces-
sarily imply susceptibility, as cell-mediated response 
(CMI) can persist. About 20% of 55-65 years old people 
do not have specific CMI, even if they have a positive 
anamnesis for varicella and are anti-VZV positive. An 
episode of zoster elicits a reactivation of T-cell specific 
response. Nowadays, there is ample consensus on the 
link between low/absent cell-mediated specific immu-
nity and incidence of zoster [22, 23].
VZV and Zoster epidemiology in Italy
In Italy, varicella is subject to mandatory notification 
and is included in the 2nd class of notifiable infectious 
diseases [24]. All reported cases are recorded by Italy’s 
National Census Bureau (ISTAT). Other databases exist 
for varicella, such as Italy’s Paediatric Sentinel Surveil-
lance System of Vaccine-Preventable Diseases (SPES) 
and the National Hospital Discharge Database (SDO). 
This latter was created in 1994 in order to collect infor-
mation on all hospitalizations recorded in Italy [25]. For 
zoster, notification is not mandatory; thus no national-
level data are available except for SDO records.
In our country, because of absence of extensive vac-
cinal intervention, varicella is an endemic-epidemic 
disease; virus spreading determines each year approxi-
mately 500,000 new cases, which correspond to a birth 
cohort [26].
The overall standardized annual incidence ranged from 
164.4 to 244.2 per 100,000 population in the years 
1991-2004. The disease mainly affected children (0-14 
years); the analysis by geographic area showed that, 
although the trend in incidence was similar for the three 
areas, there was a clear north-south gradient, with the 
highest incidence consistently found for Northern Italy, 
followed by central and then southern Italy. The evalu-
ation of SPES database has confirmed that varicella is a 
wide spread infectious disease and that the notification 
system greatly suffers from underreporting.
According to the National Hospital Discharge Database, 
in the period 2000-2003, there was an annual mean of 
1,575 hospitalizations for varicella (1,521 hospitaliza-
tions and 54 day-hospital admissions). The mean dura-
tion of stay was 5.3 days.
A seroprevalence study, recently conducted, confirmed 
that in Italy VZV infection is predominantly a paediatric 
disease, and the results did not substantially differ from 
those of a study conducted using the same methods on 
samples collected in 1996-1997 [27]. The trend in se-
roprevalence was similar for males and females; it was 
also similar when comparing the three geographic areas. 
The mean gemometric titer (GMT) showed progressive 
increase, indicating, as found in 1996-97, the existence 
of natural boosters deriving from the persistent circula-
tion of the etiological agent. Nonetheless, it should be 
stressed that, for both genders, approximately 15% of 
adolescents and 9% of subjects in the 20-39 year age 
group are susceptible.
The sero-epidemiological profile in Italy is different 
from that in other European countries. As shown by 
other Authors [28-31], in Italy, the rate of susceptible 
subjects is at least nearly twice as high as the percent-
ages in the other countries participating in the European 
Seroepidemiology Network (ESEN). This confirms that 
there are important differences in the age of disease 
acquisition, and it is consistent with the finding that, 
among the ESEN countries, Italy has the lowest repro-
duction number (R
0
) and force of infection. Moreover, 
in Italy, the high percentage of subjects who are suscep-
tible in the 20-39 year age group indicates that there is a 
concrete risk for VZV infection for pregnant women.
For zoster, notification is not mandatory and data avail-
able come from studies conducted in different areas and 
with different methodologies. However, a retrospective 
observational study conducted at national level in 1996 
involving Dermatologists, Geriatric Doctors and General 
Practitioners allowed to estimate that each year in Italy 
occur 200,000 cases of zoster and 42,000 cases of post-
herpetic neuralgia in subjects older than 15 years [32]. In 
this study, 45.8% and 44.2% of cases involved respec-
tively subjects older than 65 yrs and subjects still work-
ing. The mean duration of each case was 11-15 days and 
the overall rate of complications resulted 19.6%; PHN 
VZV INFECTION: EPIDEMIOLOGY AND PREVENTION
67
was the most common complication. Antivirals were 
prescribed in almost all patients.
The National Hospital Discharge Database, even if 
affected by underestimation, permits to evaluate the 
impact of zoster in Italy. In the period 2000-2003, there 
was an annual mean of 5,250 hospitalizations (4,711 
hospitalizations and 539 day-hospital admissions). The 
mean duration of stay was 8.3 days. Of the total hospital 
admissions for zoster, 62.1% were for subjects older 
than 65 years of age.
In the period 1992-2001, 301 deaths for zoster were re-
ported; 88.7% of these occurred in subjects > 70 years, 
probably affected by other underlying pathologies.
Preventive measures
In Italy, according to law [33], there are some preven-
tive measures to be adopted against varicella. Consider-
ing the period of contagiousness, these are:
– isolation at home for at least 5 days since the ap-
pearance of the first crop of vesicles, avoiding con-
tacts with susceptible subjects, especially pregnant 
women and newborns;
– in case of hospitalization, strict isolation taking into 
account the possibility of transmission of infection to 
susceptible immunocompromised subjects.
No restriction from school or other community at-
tendance is required for household contacts and other 
contacts.
In case of hospitalization of a contact for other reasons, 
isolation should be provided for 10-21 days since the 
last contact with a varicella case (28 days in the case of 
administration of specific immunoglobulins).
Vaccination of subjects at high risk of complications 
due to VZV infection is indicated by Circular n° 8 of 
March 10th, 1992 [34]. This circular focuses attention on 
the severe clinical course of VZV infection in subjects 
affected by chronic renal failure, lymphoproliferative 
diseases, leukemia, and in candidate recipents of bone 
marrow, liver and renal transplant.
Varicella can be prevented by the administration of spe-
cific immunoglobulins within 72-96 hours of exposure; 
this kind of intervention is indicated in immunocom-
promised subjects, susceptible pregnant women and 
newborns from mother affected by the disease between 
7 days before and 2 days after delivery.
Vaccination
The development of a vaccine against varicella has 
represented a very important task, involving many 
Researchers and taking a lot of efforts, being a vaccine 
against an herpesvirus, able to cause latent infection. 
The live, attenuated vaccine was developed by Taka-
hashi and Co-workers at the Biken Institute in Osaka, 
Japan, in the early ’70s using the virus isolated from 
a 3 years old healthy child, called Oka [35]. The virus 
strain was attenuated with 11 passages at 34 °C in hu-
man embryonic lung fibroblasts, followed by 12 passages 
at 37 °C in guinea pig fibroblasts and 5 passages at 38 °C 
in human diploid fibroblasts (Wi-38).
Nowadays, all commercially available vaccines use the 
Oka strain of VZV; however, they differ for the number 
of passages in Wi-38, the viral amount in each dose, ec-
cipients and other aspects covered by trade mark.
The vaccines available in Italy are Varivax (MSD) and 
Varilrix (GSK); both products are safe and effective [10] 
and are administered in one dose in children up to 12 years 
and in 2 doses (4-8 weeks apart) in subjects 13 years or 
older.
In terms of efficacy, both vaccines induce high serocon-
version rates; 87% and 97% of healthy children reach a 
level of antibodies considered protective after 1 and 2 
doses, respectively.
The vaccine should be administered subcutaneously and 
can be given simultaneously with other vaccines (e.g. 
Measles-Mumps-Rubella [MMR]); if co-administration 
is not possibile, it is necessary to separate the adminis-
tration of 2 vaccines > 4-6 weeks. The use of blood or 
blood products 5 months before or 3 weeks after vaccine 
administration can reduce its efficacy.
The use of several million doses worldwide has dem-
onstrated the safety of the commercially available vac-
cines; local and general side effects could be possibile, 
but they are usually moderate, self-limiting without 
sequelae.
Vaccine virus transmission is possibile but extremely 
rare and is related to a rash following administration.
Controindications to the use of VZV vaccine are the 
same adopted for all vaccine containing live, attenuated 
virus; besides, VZV vaccination should be avoided in 
pregnancy, in case of known allergy to vaccine com-
ponents or of any reaction to previous doses. In acute 
severe illness, such as untreated active tuberculosis or 
recent administration of blood, plasma or immunoglob-
ulins vaccination can be postponed until recovery or 
possibile interference ends.
Clinical trials with VZV vaccine in bone marrow 
transplants, in patients waiting for renal transplant, 
leukemic children in remission, HIV-positive children 
and children with solid tumors before chemotherapy 
have been conducted. In most cases 1 or 2 doses have 
induced a high degree of protection with mild side ef-
fects. From the practical point of view, nowadays VZV 
vaccine administration is allowed in leukemic children 
in remission and in HIV-positive subjects not severely 
immunocompromised [36].
VZV vaccine is effective in preventing illness or at least 
modifying disease severity if administered as post-ex-
posure prophylaxis. This latter should be adopted within 
3-5 days after exposure/contagion and it is indicated 
for subjcets at high risk of complications in case of 
varicella.
Since 2005 in the USA a tetravalent combined vaccine 
MMRV (measles-mumps-rubella-varicella) (Proquad, 
Merck) has been licensed and is commercially available 
for use in children aged 12 months to 12 years; more 
recently this product has been licensed and commercial-
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ized in Europe. This vaccine contains a higher dose of 
live, attenuated VZV virus in respect to the monocom-
ponent vaccine; it induces seroconversion rates > 98% 
after 2 doses and has an excellent safety and efficacy 
profile [37, 38].
Another quadrivalent combined vaccine (Priorix-Tetra, 
GSK) has recently been licensed in Germany and Aus-
tralia; safety, tolerability and efficacy of this product 
are excellent and not significantly different from what 
observed with the monocomponent vaccine already 
commercially available [39].
VZV vaccine: controversies and scientific 
debate
The main point is represented by the notification of 
varicella cases in vaccinated subjects (breakthrough in-
fection) and of epidemic outbreaks in communities with 
a high vaccination coverage rate. These cases seem to 
show a level of vaccine effectiveness lower than expect-
ed on the basis of clinical trials previously conducted.
Breakthrough infection is defined as skin lesions, gener-
ally 10-20, diagnosed as chickenpox, occurring at least 
42 days after vaccination and caused by wild-type VZV. 
A breakthrough infection can be evaluated as a primary 
(no-take) or secondary (immune response decreases 
over time) vaccine failure. Noteworthy, each case of 
breakthrough infection is infectious and represents a 
risk of virus transmission in a community.
The hypothesis of a long duration of immune protection 
following VZV vaccination has been based on the Japa-
nese data, showing that antibodies induced by vaccina-
tion were still detectable 20 yrs after immunization. It is 
important to note that this persistence has to be related 
to the ample possibility of natural boosters, being the 
vaccine coverage rate 20%.
Some Authors have verified that protective efficacy low-
ers in particular if vaccine has been administered before 
15 months of age. For this reason, in order to avoid inter-
ference due to maternal antibodies it seems appropriate 
to vaccinate children > 15 months of age and to adopt a 
second dose of vaccine [5, 10, 40]. Even if the causes of 
breakthrough varicella need to be further elucidated, the 
administration of a second dose of vaccine seems to have 
the potential to reduce primary and secondary vaccine 
failure. For these reasons, recently in the USA the Advi-
sory Committee on immunization practices (ACIP) has 
adopted new recommendations regarding the use of live, 
attenuated varicella vaccines, implementing a routine 2-
dose varicella vaccination program for children, with the 
first dose administered at 12-15 months and the second 
dose at age 4-6 years [36].
Another extremely interesting point that needs further 
studies is the possibility that immune response induced 
by vaccines containg Oka strain (Asian clade) could 
result less effective in areas, such as the USA, where 
different strains are circulating (European clade).
Finally, some Authors using mathematical models 
predict an increase of the incidence of herpes zoster 
following the first few decades of extensive infant 
varicella vaccination [41, 42]. This fact could happen 
in non-vaccinated people as the consequence of the 
reduced spreading of the wild-type VZV, to the loss 
of exogenous boosting from contacts with chickenpox 
cases and then to the waning of CMI response. Updated 
researches conducted in USA, where widespread infant 
vaccination has been adopted almost ten years ago, have 
not confirmed this hypothesis; up to now no changes in 
the trend of zoster have been registered at national level 
following the increased varicella vaccination coverage 
rate [43]. In two cases, an augmented zoster incidence 
has been registered but has been related to an increased 
use of oral steroids or to a higher rate of immunocom-
promised subjects [44, 45].
Prospectives of vaccination against her-
pes zoster
Several international researches have clearly demon-
strated the epidemiological impact of zoster, its com-
plications and related costs. Furthermore, there are no 
satisfactory treatment options for zoster complications 
and this implies additional costs and a bad quality of life 
for patients [46].
All these reasons have prompted preventive interven-
tion against zoster and, along with the development of 
the varicella vaccine, some Researchers have evaluated 
the possibility to stimulate CMI response in order to 
reduce the incidence of zoster and its complications. 
During the last ten years it has been demonstrated that 
this target can be achieved using high-potency, live, 
attenuated VZV vaccine in elderly immunocompetent 
patients [47, 48].
Recently a double blinded clinical trial has been con-
ducted in USA enrolling adults > 60 years of age. The 
subjects were treated with placebo or “zoster vaccine” 
(Oka/Merck) with a median potency of 24600 PFU, that 
means 14 times greater than varicella pediatric formula-
tion [49].
In the period September 2001-April 2004, 38,546 im-
munocompetent subjects, with positive anamnesis for 
varicella or residing in the USA for at least 30 years, 
have been enrolled and followed up. Safety and efficacy 
of the “zoster vaccine” have been investigated as well as 
its impact on the burden of illness, incidence of zoster 
and PHN.
The new vaccine turned out to be safe; low rates of 
severe adverse events, sistemic adverse events and hos-
pitalizations have been registered. Local reactions were 
usually mild and transient. The vaccine did not cause 
cases of zoster.
The impact of vaccination on the burden of disease, in-
cidence of zoster and PHN was equal to 61.1%, 51.3% 
and 66.5%, respectively.
This means that the new vaccine, increasing the CMI 
response, has a booster effect and represents a new 
option of preventive intervention against zoster and its 
complications [50, 51].
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Noteworthy, this target is achievable only using a high-
potency vaccine and up to now there are no data on the 
use of pediatric formulation in order to intervene against 
zoster and/or PHN in adults and elderly.
The vaccine, commercially available as Zostavax 
(MSD), has been licensed by FDA and in the USA there 
is the provisional recommendation for its use in a single 
dose in subjects ≥ 60 years.
At the moment no data are available on what could be 
the impact of such vaccine in relation to the age of pa-
tients treated and to the coverage rate achieved, and to 
what could be the best strategy of intervention. Possibile 
options could be to intervene in subjects > 60 years or > 
65 years, considering the already existing recommenda-
tions for flu and pneumococcal vaccinations in elderly 
and that the clinical trial conducted in USA showed the 
best results in subjects 60-69 years old.
However, there are no data on co-administration of the 
“zoster vaccine” with flu and pneumococcal vaccines, du-
ration of the protection, opportunity of subsequent boosters 
and impact in terms of costs of the different options.
Options of intervention
The epidemiological importance of varicella and zoster 
and the availability of a live, attenuated, safe and effec-
tive vaccine [5, 6] has prompted an ample international 
debate on the opportunity of an extensive vaccine inter-
vention.
At European level, European Working Group on Vari-
cella (EuroVar) has recently recommended routine 
varicella vaccination in healthy children 12-18 months 
and in all susceptible children before 13 years of age, 
catch-up immunization of older children and adults an-
amnestically negative for the disease and at high risk of 
transmission and exposure or of complications.
This kind of intervention is recommended only for coun-
tries able to rapidly achieve and maintain a high coverage 
rate [52], in order to avoid perverse effects as already 
happened for Measles, Mumps and Rubella [53].
Before evaluating the different options of intervention 
against varicella, it is necessary to have complete and 
updated epidemiological data, the acquisition of which 
entails not only performing seroepidemiological inves-
tigations but also creating or implementing passive or 
active surveillance systems for varicella and zoster. Al-
though on this point there is ample consensus, it is well 
known that not all the countries where extensive vacci-
nation campaigns are starting or planned have adequate 
surveillance systems [54].
With regard to the vaccination options, mass vac-
cination in infancy (12-18 months of age) would 
substantially decrease the spread of the disease, have 
an impact on costs and would protect subjects at high 
risk of complications. The achievement of these targets 
implies a high vaccine coverage rate in order to avoid 
an increase in the mean age of acquisition of the infec-
tion and thus in the risk of complications. For these 
reasons, the vaccine intervention should be applied to 
children 12-18 months of age and in all susceptible 
subjects before 13 years [52]. In addition, a second 
dose should be adopted in order to guarantee the catch 
up of non responders to the first dose and to reduce the 
secondary vaccine failure [36, 40].
The immunization of susceptible adolescents and adults 
would represent an alternative option. This type of 
intervention would have a limited impact on the epi-
demiology of the infection, but it would contribute to 
decrease the incidence among persons at greatest risk of 
complications.
There is a theoretical negative impact of mass vaccination 
in terms of increasing the incidence of zoster, given that 
exposure to VZV boosts natural immunity [41]. This risk 
needs to be carefully considered; however, data currently 
available do not support this hypothesis [43]. Moreover, 
the possibility of using a vaccine with a high antigen titer 
for preventing zoster in adults is being considered [51].
In Italy, we are still in a pre-vaccine era; some Regions 
(Sicilia, Veneto, Puglia) have started or planned uni-
versal vaccination, others (Liguria, Piemonte, Valle 
d’Aosta, Emilia Romagna, Toscana, Basilicata, Campa-
nia, Lazio) have decided to immunize susceptible ado-
lescents, while others (Lombardia, Trentino Alto Adige, 
Marche, Abruzzo, Umbria, Molise, Calabria, Sardegna) 
have not decided on any type of intervention.
Italy’s 2005-2007 National Vaccination Plan [55] rec-
ommends vaccinating persons at high risk of complica-
tions, susceptible adolescents, healthcare workers, and 
the staff of day-care centres and schools with small chil-
dren. Mass vaccination is only recommended in regions 
where a vaccination coverage of greater than 80% for 
MMR can be achieved. A cluster sampling survey con-
ducted in 2003 revealed a national MMR vaccination cov-
erage of 77%, in children aged 13-24 months of age [56] 
and routine coverage data provided by Regions to the 
Italian Ministry of Health in 2004 showed an MMR vac-
cination coverage of 85.5%. It is therefore possible that 
in a near future the conditions necessary for implement-
ing a mass vaccination campaign will exist and that the 
large-scale availability of MMRV tetravalent vaccines 
will facilitate this strategy of intervention.
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